FR2830198A1 - Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors - Google Patents
Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors Download PDFInfo
- Publication number
- FR2830198A1 FR2830198A1 FR0112543A FR0112543A FR2830198A1 FR 2830198 A1 FR2830198 A1 FR 2830198A1 FR 0112543 A FR0112543 A FR 0112543A FR 0112543 A FR0112543 A FR 0112543A FR 2830198 A1 FR2830198 A1 FR 2830198A1
- Authority
- FR
- France
- Prior art keywords
- sep
- aromatica
- pharmaceutical compositions
- essential
- ravensara
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 244000062757 Cryptocarya agathophylla Species 0.000 title claims abstract description 14
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 title claims description 6
- 201000003883 cystic fibrosis Diseases 0.000 title claims description 4
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 208000001756 Virus Disease Diseases 0.000 title claims 2
- 208000006551 Parasitic Disease Diseases 0.000 title description 3
- 206010017533 Fungal infection Diseases 0.000 title description 2
- 206010047461 Viral infection Diseases 0.000 title 1
- 240000005147 Syzygium aromaticum Species 0.000 claims abstract description 11
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 11
- 244000302413 Carum copticum Species 0.000 claims abstract description 9
- 235000007034 Carum copticum Nutrition 0.000 claims abstract description 9
- 235000003515 Lavandula officinalis Nutrition 0.000 claims abstract description 9
- 241000378544 Melaleuca quinquenervia Species 0.000 claims abstract description 9
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 8
- 240000003982 Ocimum basilicum Species 0.000 claims abstract description 8
- 240000001422 Laurus nobilis Species 0.000 claims abstract description 7
- 235000017858 Laurus nobilis Nutrition 0.000 claims abstract description 7
- 240000002776 Cymbopogon martinii Species 0.000 claims abstract description 6
- 235000005241 Cistus ladanifer Nutrition 0.000 claims abstract description 4
- 240000008772 Cistus ladanifer Species 0.000 claims abstract description 4
- 235000010695 Eucalyptus radiata Nutrition 0.000 claims abstract description 4
- 240000003060 Eucalyptus radiata Species 0.000 claims abstract description 4
- 241000605535 Aniba Species 0.000 claims abstract description 3
- 235000018793 Cymbopogon martinii Nutrition 0.000 claims abstract description 3
- 241001142049 Dittrichia graveolens Species 0.000 claims abstract description 3
- 235000018625 Helichrysum angustifolium Nutrition 0.000 claims abstract description 3
- 240000008824 Helichrysum italicum Species 0.000 claims abstract description 3
- 235000013530 Helichrysum italicum Nutrition 0.000 claims abstract description 3
- 240000008272 Lavandula officinalis Species 0.000 claims abstract description 3
- 244000258329 Ledum groenlandicum Species 0.000 claims abstract description 3
- 235000000386 Ledum groenlandicum Nutrition 0.000 claims abstract description 3
- 241000366182 Melaleuca alternifolia Species 0.000 claims abstract description 3
- 241001537288 Origanum compactum Species 0.000 claims abstract description 3
- 235000002328 Origanum compactum Nutrition 0.000 claims abstract description 3
- 210000001541 Thymus Gland Anatomy 0.000 claims abstract description 3
- 239000000969 carrier Substances 0.000 claims abstract description 3
- 239000003085 diluting agent Substances 0.000 claims abstract description 3
- 230000001225 therapeutic Effects 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000003921 oil Substances 0.000 claims description 17
- 240000005183 Lantana involucrata Species 0.000 claims description 9
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 9
- 235000006677 lemon beebalm Nutrition 0.000 claims description 9
- 235000004383 oregano Nutrition 0.000 claims description 9
- 235000018838 origanum vulgare Nutrition 0.000 claims description 9
- 240000004499 Cinnamomum aromaticum Species 0.000 claims description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 7
- 244000165082 Lavanda vera Species 0.000 claims description 6
- 235000010701 Lavanda vera Nutrition 0.000 claims description 6
- 240000003136 Rosmarinus officinalis Species 0.000 claims description 6
- 235000017803 cinnamon Nutrition 0.000 claims description 6
- 239000001102 lavandula vera Substances 0.000 claims description 6
- 235000018219 lavender Nutrition 0.000 claims description 6
- 241001247986 Calotropis procera Species 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 244000105627 Cajanus indicus Species 0.000 claims description 4
- 235000010773 Cajanus indicus Nutrition 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 4
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 4
- 240000002657 Thymus vulgaris Species 0.000 claims description 4
- 239000001585 thymus vulgaris Substances 0.000 claims description 4
- 241000608894 Helichrysum Species 0.000 claims description 3
- 241000132446 Inula Species 0.000 claims description 3
- 240000008251 Pterocarpus indicus Species 0.000 claims description 3
- 235000009984 Pterocarpus indicus Nutrition 0.000 claims description 3
- 235000017304 Ruaghas Nutrition 0.000 claims description 3
- 235000000212 Solanum linnaeanum Nutrition 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 241000984090 Cistus Species 0.000 claims description 2
- 241000282816 Giraffa camelopardalis Species 0.000 claims description 2
- 210000004080 Milk Anatomy 0.000 claims description 2
- -1 biogranules (malt) Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000002538 fungal Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000002458 infectious Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- 235000002548 Cistus Nutrition 0.000 claims 1
- 230000003071 parasitic Effects 0.000 claims 1
- 241000220442 Cajanus Species 0.000 abstract 1
- 241001072909 Salvia Species 0.000 abstract 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 69
- 235000019198 oils Nutrition 0.000 description 16
- 230000000840 anti-viral Effects 0.000 description 8
- 241000494043 Ravensara Species 0.000 description 7
- 240000001200 Eucalyptus globulus Species 0.000 description 6
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 6
- 235000010705 Eucalyptus maculata Nutrition 0.000 description 6
- 235000009683 Eucalyptus polybractea Nutrition 0.000 description 6
- 235000009687 Eucalyptus sargentii Nutrition 0.000 description 6
- 235000001612 eucalyptus Nutrition 0.000 description 6
- 235000001617 eucalyptus Nutrition 0.000 description 6
- 235000001621 eucalyptus Nutrition 0.000 description 6
- 235000006356 eucalyptus Nutrition 0.000 description 6
- 235000005227 red mallee Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- MXXWOMGUGJBKIW-YPCIICBESA-N Piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 4
- 230000002924 anti-infective Effects 0.000 description 4
- 230000003344 immunostimulant Effects 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 240000007742 Raphanus sativus Species 0.000 description 3
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 3
- 150000002773 monoterpene derivatives Chemical class 0.000 description 3
- 229930003658 monoterpenes Natural products 0.000 description 3
- 235000002577 monoterpenes Nutrition 0.000 description 3
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 229940109501 Eucalyptol Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 230000000855 fungicidal Effects 0.000 description 2
- 230000000590 parasiticidal Effects 0.000 description 2
- 230000000149 penetrating Effects 0.000 description 2
- 229940075559 piperine Drugs 0.000 description 2
- 235000019100 piperine Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N (+-)-(RS)-limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- AYXPYQRXGNDJFU-IMNVLQEYSA-N (1aR,4S,4aS,7R,7aS,7bS)-1,1,4,7-tetramethyl-2,3,4a,5,6,7,7a,7b-octahydro-1aH-cyclopropa[e]azulen-4-ol Chemical compound [C@@H]1([C@@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-IMNVLQEYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 229940116257 Pepper extract Drugs 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 240000000129 Piper nigrum Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N Thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- AYXPYQRXGNDJFU-BFWDZPHWSA-N Viridiflorol Natural products O[C@]1(C)[C@@H]2[C@H]([C@H](C)CC2)[C@@H]2C(C)(C)[C@@H]2CC1 AYXPYQRXGNDJFU-BFWDZPHWSA-N 0.000 description 1
- 210000000707 Wrist Anatomy 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000001390 anti-relaxing Effects 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 230000002026 carminative Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000003419 expectorant Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007650 limonene Natural products 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229930007823 thymol Natural products 0.000 description 1
- 125000003639 thymyl group Chemical group C1(=CC(C)=CC=C1C(C)C)* 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
<Desc/Clms Page number 1> <Desc / Clms Page number 1>
COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES HUILES
ESSENTIELLES ET LEURS UTILISATIONS La présente invention se rapporte à l'utilisation de plantes ou de parties de plantes, pour la réalisation de compositions pharmaceutiques. PHARMACEUTICAL COMPOSITIONS COMPRISING OILS
The present invention relates to the use of plants or parts of plants for producing pharmaceutical compositions.
L'invention concerne plus particulièrement des compositions pharmaceutiques renfermant principalement de l'huile essentielle de Ravensara aromatica (Agathophyllum aromatica) associée à d'autres extraits de plantes. The invention more particularly relates to pharmaceutical compositions containing mainly Ravensara aromatica essential oil (Agathophyllum aromatica) combined with other plant extracts.
Elle a spécifiquement pour objet des compositions pharmaceutiques caractérisées en ce qu'elles contiennent principalement de l'huile essentielle de Ravensara aromatica associée à d'autres huiles essentielles choisies parmi l'Origan (Origanum compactum), le Niaouli (Melaleuca quinquenervia), l'Hélichryse (Helichrysum italicum), le Laurier noble (Laurus nobilis), l'Ajowan (Trachyspermum ammi), le Giroflier (Eugenia aromatica et Eugenia caryophyllata), l'inule odorante (Inula graveolens), le Palmarosa (Cymbopogon martinii), le Romarin (Rosmarinus officinalis), l'Eucalyptus radié (Eucalyptus radiata), le Basilic (Ocimum basilicum), la Lavande aspic (Lavandula spica), les Thym (Thymus officinalis et autres), la Ciste
ladanifère (Cistus ladanifer), le bois de rose (Aniba rosaedora), le Tea Tree (Melaleuca alternifolia), la Cannelle de Chine (Cinnanomum cassia et Cinnanomum aromaticum), le Ledon du groënland (Ledum groenlandicum), la Pomme de Sodome (Calotropis procera) et le Pois d'Angole (Cajanus cajan) dans un excipient, un véhicule ou un diluant approprié pour l'usage thérapeutique. It relates specifically to pharmaceutical compositions characterized in that they contain mainly the essential oil of Ravensara aromatica combined with other essential oils selected from the oregano (Origanum compactum), the Niaouli (Melaleuca quinquenervia), the Helichrysum (Helichrysum italicum), the noble laurel (Laurus nobilis), the Ajowan (Trachyspermum ammi), the Giraffe (Eugenia aromatica and Eugenia caryophyllata), the fragrant inula (Inula graveolens), the Palmarosa (Cymbopogon martinii), the Rosemary (Rosmarinus officinalis), Eucalyptus radish (Eucalyptus radiata), Basil (Ocimum basilicum), Lavender aspic (Lavandula spica), Thyme (Thymus officinalis and others), Cistus
ladanifer (Cistus ladanifer), rosewood (Aniba rosaedora), Tea Tree (Melaleuca alternifolia), Chinese cinnamon (Cinnanomum cassia and Cinnanomum aromaticum), Greenland Ledon (Ledum groenlandicum), Sodom apple (Calotropis procera) and pigeon pea (Cajanus cajan) in a carrier, vehicle or diluent suitable for therapeutic use.
Les huiles essentielles peuvent également être utilisées telles quelles. Essential oils can also be used as is.
Les compositions pharmaceutiques selon l'invention peuvent contenir en outre un extrait de Poivrier (Piper nigrum ou Piper longum) ou de la pipérine qui renforce sensiblement les effets des principes actifs contenus dans les huiles essentielles des plantes utilisées dans la présente invention. The pharmaceutical compositions according to the invention may also contain a pepper extract (Piper nigrum or Piper longum) or piperine which substantially enhances the effects of the active principles contained in the essential oils of the plants used in the present invention.
<Desc/Clms Page number 2> <Desc / Clms Page number 2>
Les compositions pharmaceutiques selon l'invention s'adressent plus particulièrement au traitement des affections virales, et/ou infectieuses, et/ou fongiques, et/ou parasitaires, des maladies comme la mucoviscidose, des immunodéficiences telles que le SIDA et le traitement de certaines tumeurs. The pharmaceutical compositions according to the invention are more particularly intended for the treatment of viral and / or infectious and / or fungal and / or parasitic diseases, diseases such as cystic fibrosis, immunodeficiencies such as AIDS and the treatment of certain diseases. you die.
Les propriétés anti-infectieuses et antivirales de Ravensara aromatica sont connues et utilisées en aromathérapie. Les rameaux feuillus de Ravensara aromatica sont utilisés traditionnellement en infusion comme stomachique et carminatif et en sirop comme expectorant. The anti-infectious and antiviral properties of Ravensara aromatica are known and used in aromatherapy. The leafy twigs of Ravensara aromatica are traditionally used in infusion as stomachic and carminative and in syrup as expectorant.
Les jeunes rameaux feuillus fournissent l'huile essentielle qui possède des propriétés neurotoniques, immunostimulantes, antivirales, anti infectieuses et décontractantes. The young hardwood twigs provide the essential oil which has neurotonic, immunostimulant, antiviral, anti-infectious and relaxing properties.
De même les huiles essentielles des autres plantes utilisées dans les compositions pharmaceutiques de la présente invention sont connues pour leurs propriétés fongicides (Ajowan, Lavande aspic, Clou de Girofle, Origan), antivirales (Eucalyptus), parasiticide (Ajowan, Cannelle de Chine) et immunostimulantes (Clou de Girofle, Eucalyptus, Origan). Similarly, the essential oils of the other plants used in the pharmaceutical compositions of the present invention are known for their fungicidal properties (Ajowan, Lavande aspic, Clove, Oregano), antiviral (Eucalyptus), parasiticide (Ajowan, Cinnamon from China) and immunostimulant (Clove, Eucalyptus, Oregano).
Par exemple, le Niaouli est réputé comme ayant des propriétés anti-infectieuses, anti-fongiques et antivirales. L'huile essentielle de cette plante, riche en oxydes monoterpéniques (45 à 60% de 1-8 cinéole), en monoterpène (10 % d'a-pinène, 5 à 9 % de limonène), en sesquiterpénols (2 à 10% de viridiflorol) est utilisée pour traiter les infections des voies respiratoires, la grippe et l'herpès. For example, Niaouli is reputed to have anti-infective, anti-fungal and antiviral properties. The essential oil of this plant, rich in monoterpene oxides (45 to 60% of 1-8 cineole), in monoterpene (10% of a-pinene, 5 to 9% of limonene), in sesquiterpenols (2 to 10% viridiflorol) is used to treat infections of the respiratory tract, influenza and herpes.
L'association d'Eucalyptus radié, d'Hélichryse, d'Inule odorante, de Laurier noble, de Lavande aspic, de Romarin, de Niaouli et de Ravensara aromatica forme une composition pharmaceutique idéale pour le traitement de la mucoviscidose. The combination of Eucalyptus radish, Helichryse, Inula fragrant, Laurel noble, Lavender aspic, Rosemary, Niaouli and Ravensara aromatica forms an ideal pharmaceutical composition for the treatment of cystic fibrosis.
L'association d'Ajowa, de Cannelle de Chine, de Clou de Girofle, de Laurier noble,, de Lavande aspic, d'Origan et de Ravensara forme une composition pharmaceutique idéale pour le traitement des infections fongiques. The combination of Ajowa, Chinese Cinnamon, Clove, Laurel, Lavender Aspic, Oregano and Ravensara forms an ideal pharmaceutical composition for the treatment of fungal infections.
<Desc/Clms Page number 3> <Desc / Clms Page number 3>
L'association d'Ajowan, d'écorce de Cannelle de Chine, de Clou de Girofle, de Tea Tree et de Thym thymol forme une composition pharmaceutique idéale pour le traitement des infections parasitaires. The combination of Ajowan, Chinese Cinnamon Bark, Clove, Tea Tree and Thym Thymol forms an ideal pharmaceutical composition for the treatment of parasitic infections.
L'association de Ravensara, d'extrait de graines de Pois d'Angole et de Pomme de Sodome forme une composition pharmaceutique idéale pour le traitement de la drépanocytose. The combination of Ravensara, pea seed extract and Sodom apple forms an ideal pharmaceutical composition for the treatment of sickle cell disease.
L'association d'Ajowan, de bois de Rose, de Cannelle de Chine, de Ciste ladanifère, d'Eucalyptus radié, de Clou de Girofle, de Lavande aspic, d'Origan, de Tea Tree, de Thym thymol, de Thym thujanol, de Ravensara et de Palmarosa forme une composition pharmaceutique idéale pour le traitement de l'immunodéficience humaine (SIDA). The combination of Ajowan, Rosewood, Chinese Cinnamon, Rockrose Cistus, Eucalyptus Radish, Clove, Lavender Aspic, Oregano, Tea Tree, Thym Thymol, Thyme Thujanol , Ravensara and Palmarosa form an ideal pharmaceutical composition for the treatment of human immunodeficiency (AIDS).
L'association de Ravensara, de Ledon du groenland, de Basilic exotique, de Thym thujanol et de Romarin forme une composition pharmaceutique idéale pour le traitement des hépatites. The combination of Ravensara, Ledon Greenland, Exotic Basil, Thyme Thyuanol and Rosemary forms an ideal pharmaceutical composition for the treatment of hepatitis.
On peut également citer à cet égard la demande de brevet FR 2 709 964 qui a pour objet l'utilisation de Ravensara aromatica en association avec certaines variétés de Lavande, de Niaouli, de Basilic, avec du sulfate de zinc, de l'oxyde de zinc et du sulfate de cuivre, pour le traitement de l'herpès et de l'immunodéficience humaine (SIDA). One can also cite in this regard the patent application FR 2 709 964 which relates to the use of Ravensara aromatica in combination with certain varieties of Lavender, Niaouli, Basil, with zinc sulfate, the oxide of zinc and copper sulfate, for the treatment of herpes and human immunodeficiency (AIDS).
Les compositions pharmaceutiques selon la présente invention sont nettement plus actives. The pharmaceutical compositions according to the present invention are significantly more active.
Les compositions pharmaceutiques de la présente invention contiennent de 30% à 80% d'huile essentielle de Ravensara aromatica qui est riche en 1-8 cinéole, un oxyde monoterpénique dont les propriétés antivirales, immunostimulantes et anti bactériennes sont déjà connues. The pharmaceutical compositions of the present invention contain from 30% to 80% of Ravensara aromatica essential oil which is rich in 1-8 cineole, a monoterpene oxide whose antiviral, immunostimulant and anti-bacterial properties are already known.
L'intérêt de la présente invention est l'obtention de compositions pharmaceutiques contenant principalement de l'huile essentielle de Ravensara aromatica, en association avec d'autres extraits de plantes pour obtenir une potentialisation des The advantage of the present invention is the production of pharmaceutical compositions containing mainly the essential oil of Ravensara aromatica, in combination with other plant extracts to obtain a potentiation of
<Desc/Clms Page number 4><Desc / Clms Page number 4>
effets antiviraux, anti infectieux, fongicides, parasiticides, immunostimulants et/ou anticancéreux. antiviral, anti-infectious, fungicidal, parasiticidal, immunostimulant and / or anticancer effects.
Les compositions de la présente invention peuvent être appliquées localement notamment sous la forme de mélanges d'huiles essentielles brutes ou bien d'émulsions H/E ou E/H, de gels, de pommades, d'huiles, de laits, de liposomes. Les compositions pharmaceutiques peuvent également être administrées par voie orale, per-cutanéee, ou rectale, selon les cas, sous la forme de capsules molles, de gélules, de biogranules (malt), de suppositoire, de solutions ou d'émulsions huileuses. The compositions of the present invention may be applied locally, especially in the form of mixtures of crude essential oils or of O / W or W / O emulsions, gels, ointments, oils, milks or liposomes. The pharmaceutical compositions can also be administered orally, percutaneously or rectally, as appropriate, in the form of soft capsules, capsules, biogranules (malt), suppository, solutions or oily emulsions.
De façon avantageuse, les compositions pharmaceutiques sont présentées sous la forme de mélange d'huiles essentielles dispersée dans une huile pénétrante et peuvent être utilisées en massage sur le thorax, les poignets et la nuque, à raison de 8 à 12 gouttes, trois fois par jour. Advantageously, the pharmaceutical compositions are presented in the form of a mixture of essential oils dispersed in a penetrating oil and can be used in massage on the thorax, wrists and nape, at a rate of 8 to 12 drops, three times per day. day.
Parmi les huiles pénétrantes ou pourra citer l'huile d'amande douce, l'huile de noisette ou l'huile de bourrache. Penetrating oils include sweet almond oil, hazelnut oil or borage oil.
Des exemples non limitatifs de compositions pharmaceutiques selon l'invention sont présentés ci-dessous : - Composition pour application topique antivirale (SIDA)
<tb>
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ravensara <SEP> aromatica <SEP> 30%
<tb> Huile <SEP> essentielle <SEP> d'Origan <SEP> compactum <SEP> 10%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Niaouli <SEP> 6%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Laurier <SEP> noble <SEP> 8%
<tb> Huile <SEP> essentielle <SEP> d'Eucalyptus <SEP> radiata <SEP> 6%
<tb> Huile <SEP> d'Amande <SEP> douce <SEP> 40%
<tb>
- Composition orale pour usage anti-cancéreux : <Tb>
<tb> Oil <SEP> essential <SEP> of <SEP> Ravensara <SEP> aromatica <SEP> 30%
<tb> Oil <SEP> essential <SEP> Oregano <SEP> compactum <SEP> 10%
<tb> Oil <SEP> essential <SEP> of <SEP> Niaouli <SEP> 6%
<tb> Oil <SEP> essential <SEP> of <SEP> Laurel <SEP> noble <SEP> 8%
<tb> Oil <SEP> essential <SEP> of Eucalyptus <SEP> radiata <SEP> 6%
<tb> Oil <SEP> Almond <SEP> Sweet <SEP> 40%
<Tb>
- Oral composition for anti-cancer use:
<Desc/Clms Page number 5> <Desc / Clms Page number 5>
<tb>
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ravensara <SEP> aromatica <SEP> 60%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ledum <SEP> groenlandicum <SEP> 10%
<tb> Huile <SEP> essentielle <SEP> d'Helichrysum <SEP> italicum <SEP> 10%
<tb> Poloxamer <SEP> 188 <SEP> 2%
<tb> Véhicule <SEP> aqueux <SEP> qsp <SEP> 100%
<tb>
Les compositions selon l'invention peuvent encore être formées d'une émulsion buvable répartie en ampoules.
<tb> Oil <SEP> essential <SEP> from <SEP> Ravensara <SEP> aromatica <SEP> 60%
<tb> Oil <SEP> essential <SEP> of <SEP> Ledum <SEP> groenlandicum <SEP> 10%
<tb> Oil <SEP> essential <SEP> of Helichrysum <SEP> italicum <SEP> 10%
<tb> Poloxamer <SEP> 188 <SEP> 2%
<tb> Vehicle <SEP> aqueous <SEP> qsp <SEP> 100%
<Tb>
The compositions according to the invention may also be formed of an oral emulsion distributed in ampoules.
<tb>
<tb> <Tb>
<Tb>
- <SEP> Suspension <SEP> buvable <SEP> antivirale
<tb> Huile <SEP> essentielle <SEP> de <SEP> Ravensara <SEP> aromatica <SEP> 40%
<tb> Huile <SEP> essentielle <SEP> d'Origan <SEP> compactum <SEP> 4%
<tb> Huile <SEP> essentielle <SEP> de <SEP> Lavande <SEP> aspic <SEP> 8%
<tb> Hydroxy-éthyl-cellulose <SEP> 2%
<tb> Hydroxy-propyl-méthyl-cell <SEP> ulose <SEP> 4%
<tb> Tween <SEP> 80 <SEP> 0,2%
<tb> Eau <SEP> purifiée <SEP> qsp <SEP> 100%
<tb>
- Capsules molles On dissout dans 100ml d'huile de germe de blé, un mélange de 60% d'huile essentielle de Ravensara aromatica, 20% d'huile essentielle d'Origan, et de 20% d'huile essentielle de Basilic. On ajoute au mélange 0,1 g de pipérine et on homogénéise le mélange. - <SEP> Suspension <SEP> drinkable <SEP> antiviral
<tb> Oil <SEP> essential <SEP> from <SEP> Ravensara <SEP> aromatica <SEP> 40%
<tb> Oil <SEP> essential <SEP> Oregano <SEP> compactum <SEP> 4%
<tb> Oil <SEP> essential <SEP> of <SEP> Lavender <SEP> aspic <SEP> 8%
<tb> Hydroxyethylcellulose <SEP> 2%
<tb> Hydroxy-propyl-methyl-cell <SEP> ulose <SEP> 4%
<tb> Tween <SEP> 80 <SEP> 0.2%
<tb> Water <SEP> purified <SEP> qsp <SEP> 100%
<Tb>
- Soft capsules In 100ml of wheat germ oil, a mixture of 60% of Ravensara aromatica essential oil, 20% of Oregano essential oil and 20% of Basil essential oil is dissolved. 0.1 g of piperine is added to the mixture and the mixture is homogenized.
Le mélange est ensuite réparti en capsules de gélatine contenant chacune 0,2g de la solution huileuse.The mixture is then distributed into gelatin capsules each containing 0.2 g of the oily solution.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112543A FR2830198B1 (en) | 2001-09-28 | 2001-09-28 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112543A FR2830198B1 (en) | 2001-09-28 | 2001-09-28 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2830198A1 true FR2830198A1 (en) | 2003-04-04 |
| FR2830198B1 FR2830198B1 (en) | 2004-10-15 |
Family
ID=8867745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0112543A Expired - Fee Related FR2830198B1 (en) | 2001-09-28 | 2001-09-28 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESSENTIAL OILS AND USES THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2830198B1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006087039A1 (en) * | 2005-02-17 | 2006-08-24 | Propharex Sa | Broad spectrum anti viral herbal composition |
| WO2007116062A1 (en) * | 2006-04-11 | 2007-10-18 | Swiss Caps Rechte Und Lizenzen Ag | Capsules containing plant preparations |
| ES2340352A1 (en) * | 2008-06-06 | 2010-06-01 | Pedro Enrique Alonso Hernandez | Unguent or liquid of topical application for wounds. (Machine-translation by Google Translate, not legally binding) |
| WO2010076730A1 (en) * | 2009-01-02 | 2010-07-08 | Donald, Jenny | Method for the treatment of an hiv infection |
| WO2011001208A1 (en) * | 2009-06-29 | 2011-01-06 | Csir | The use of an extract of helichrysum, for the treatment of hiv/aids |
| WO2011104489A2 (en) * | 2010-02-26 | 2011-09-01 | L'oreal | Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses |
| WO2011104490A2 (en) * | 2010-02-26 | 2011-09-01 | L'oreal | Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses |
| US20110293757A1 (en) * | 2008-07-18 | 2011-12-01 | Novasel Australia Pty. Ltd. | Compositions Comprising Tea Tree Oil and Methods for the Prevention and Treatment of Cancer |
| US8147878B2 (en) | 2006-01-17 | 2012-04-03 | Aboca S.P.A. Societa' Agricola | Water insoluble helychrisum extract, process for preparing the same and uses thereof |
| WO2013164442A1 (en) * | 2012-05-04 | 2013-11-07 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Plant extract for the treatment of an hiv infection as well as products relating thereto |
| RU2704038C1 (en) * | 2018-04-25 | 2019-10-23 | Светлана Александровна Чубатова | Basic composition for preparation of biologically active means of human environment treatment |
| CN112220891A (en) * | 2019-06-26 | 2021-01-15 | 株式会社Sd生命工学 | Antibacterial and antifungal composition containing herbal mixed essential oil as effective component |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2709964A1 (en) * | 1993-09-14 | 1995-03-24 | Dupont Paul | Antiviral pharmaceutical compositions proposed in the treatment of AIDS and herpes |
-
2001
- 2001-09-28 FR FR0112543A patent/FR2830198B1/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2709964A1 (en) * | 1993-09-14 | 1995-03-24 | Dupont Paul | Antiviral pharmaceutical compositions proposed in the treatment of AIDS and herpes |
Non-Patent Citations (3)
| Title |
|---|
| ARCHIVES DE L'INSTITUT PASTEUR DE MADAGASCAR, vol. 56, no. 1, 1989, pages 261 - 272, ISSN: 0020-2495 * |
| DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, RAHARIVELOMANANA P J ET AL: "CONTRIBUTION TO THE STUDY OF THE ANTIMICROBIAL ACTION OF SOME ESSENTIAL OILS EXTRACTED FROM PLANTS OF MADAGASCAR II. LAURACEAE", XP002203138, Database accession no. PREV199090078851 * |
| MEDICI DE D ET AL: "Chemical analysis of essential oils of Malagasy medicinal plants by gas chromatography and NMR spectroscopy", BIOSIS, XP002168060 * |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006087039A1 (en) * | 2005-02-17 | 2006-08-24 | Propharex Sa | Broad spectrum anti viral herbal composition |
| US8147878B2 (en) | 2006-01-17 | 2012-04-03 | Aboca S.P.A. Societa' Agricola | Water insoluble helychrisum extract, process for preparing the same and uses thereof |
| WO2007116062A1 (en) * | 2006-04-11 | 2007-10-18 | Swiss Caps Rechte Und Lizenzen Ag | Capsules containing plant preparations |
| CH699154B1 (en) * | 2006-04-11 | 2010-01-29 | Swiss Caps Rechte & Lizenzen | Capsule containing plant preparations. |
| ES2340352A1 (en) * | 2008-06-06 | 2010-06-01 | Pedro Enrique Alonso Hernandez | Unguent or liquid of topical application for wounds. (Machine-translation by Google Translate, not legally binding) |
| US20110293757A1 (en) * | 2008-07-18 | 2011-12-01 | Novasel Australia Pty. Ltd. | Compositions Comprising Tea Tree Oil and Methods for the Prevention and Treatment of Cancer |
| WO2010076730A1 (en) * | 2009-01-02 | 2010-07-08 | Donald, Jenny | Method for the treatment of an hiv infection |
| WO2011001208A1 (en) * | 2009-06-29 | 2011-01-06 | Csir | The use of an extract of helichrysum, for the treatment of hiv/aids |
| US9919019B2 (en) | 2010-02-26 | 2018-03-20 | L'oreal | Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses |
| FR2956814A1 (en) * | 2010-02-26 | 2011-09-02 | Oreal | USE OF ESSENTIAL OIL OF ORIGAN OR ROSE WOOD, OR THEIR CONSTITUENTS, IN THE COSMETIC TREATMENT OF KERATOSES |
| WO2011104490A2 (en) * | 2010-02-26 | 2011-09-01 | L'oreal | Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses |
| WO2011104489A3 (en) * | 2010-02-26 | 2012-03-22 | L'oreal | Use of essential oil of oregano or of rosewood in the treatment of actinic keratoses |
| WO2011104490A3 (en) * | 2010-02-26 | 2012-03-22 | L'oreal | Use of essential oil of oregano or of rosewood for the treatment of cancerous keratoses |
| WO2011104489A2 (en) * | 2010-02-26 | 2011-09-01 | L'oreal | Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses |
| FR2956817A1 (en) * | 2010-02-26 | 2011-09-02 | Oreal | USE OF ESSENTIAL OIL OF ORIGAN OR ROSE WOOD, OR THEIR CONSTITUENTS, IN THE THERAPEUTIC TREATMENT OF KERATOSES |
| US9040103B2 (en) | 2010-02-26 | 2015-05-26 | L'oreal | Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses |
| WO2013164442A1 (en) * | 2012-05-04 | 2013-11-07 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Plant extract for the treatment of an hiv infection as well as products relating thereto |
| RU2704038C1 (en) * | 2018-04-25 | 2019-10-23 | Светлана Александровна Чубатова | Basic composition for preparation of biologically active means of human environment treatment |
| WO2019209136A1 (en) * | 2018-04-25 | 2019-10-31 | Chubatova Svetlana Alexandrovna | Basic composition for producing a biologically active agent |
| CN112105372A (en) * | 2018-04-25 | 2020-12-18 | S·A·丘巴托娃 | Base composition for the production of bioactive agents |
| JP2021522339A (en) * | 2018-04-25 | 2021-08-30 | チュバトヴァ スヴェトラーナ アレキサンドロヴナＣＨＵＢＡＴＯＶＡ， Ｓｖｅｔｌａｎａ Ａｌｅｘａｎｄｒｏｖｎａ | Basic composition for the production of biologically active agents |
| CN112220891A (en) * | 2019-06-26 | 2021-01-15 | 株式会社Sd生命工学 | Antibacterial and antifungal composition containing herbal mixed essential oil as effective component |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2830198B1 (en) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lawless | The Encyclopedia of essential oils: the complete guide to the use of aromatic oils in aromatherapy, herbalism, health, and well being | |
| EP0870507A1 (en) | Synergistic herbal extracts | |
| JP2005533767A (en) | Terpene base material composition, preparation method thereof, and atmospheric spraying method | |
| FR2830198A1 (en) | Compositions containing Ravensara aromatica essential oil and one or more other essential oils for treatment of viral, fungal, and parasitic infections, cystic fibrosis, AIDS, and certain tumors | |
| US8268367B2 (en) | Topical herbal formulation for treatment of acne and skin disorders | |
| US20110150995A1 (en) | Solid Dosage Forms of Essential Oils | |
| US8535737B2 (en) | Composition with extracts from olive leaf, yarrow and rosemary for treating human diseases and conditions | |
| US5948414A (en) | Herbal based nasal spray | |
| CA2763458A1 (en) | Topical micro-emulsions for the treatment of rheumatic disorders | |
| FR2504551A1 (en) | Compsn. for treating skin, e.g. burns, eczema or acne - contains essential oils from Labiatae and other plant families | |
| US8821948B2 (en) | Therapeutic, bio-affecting and body treating composition | |
| Stiles | The essential oils complete reference guide: Over 250 recipes for natural wholesome aromatherapy | |
| JP6847656B2 (en) | Topical composition | |
| US20100143508A1 (en) | Limonene and yucca medical compound for treating human diseases and conditions | |
| EP3337487B1 (en) | Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof | |
| EP1049480B1 (en) | Herbal anti-viral agent | |
| JP2002241310A (en) | Locally applying composition | |
| MX2012008419A (en) | Improved composition based on terpenoids and chloretone, and the use thereof in nasal items. | |
| JPH09502455A (en) | Immune-enhancing nutritional supplement | |
| WO2017206014A1 (en) | Long-acting mosquito repellent containing extracts of traditional chinese medicines | |
| WO2022097042A1 (en) | Novel therapeutic composition based on essential oils at low doses | |
| US229874A (en) | Christian dengel | |
| CN1190190C (en) | Antiviral and antibacterial cantharidinic anhydride medicine composition and its prepn process | |
| JP2021050246A (en) | External composition | |
| WO2016044903A1 (en) | Chemical compositions for the elaboration of an organic antimicrobial spray |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20140530 |